Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
ZEJULA (niraparib) is indicated:1
- as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
- as monotherapy for the maintenance treatment of adult patients with platinum-based relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
ZEJULA licence by biomarker status
Figure adapted from Konstantinopoulos P, et al. 2025.5
Approximately 50% of advanced ovarian cancer patients are HRd- BRCAwt, 25% HRd+ BRCAmut, and 25% HRd+ BRCAwt.4 ZEJULA's indication covers all biomarker subgroups.5
References
- ZEJULA (niraparib) Summary of Product Characteristics. September 2025.
- González Martín A, et al. N Engl J Med. 2019;381(25):2391–2402.
- Monk B, et al. Ann Oncol. 2024;35(11):981–992.
- Li N, et al. JAMA Oncol. 2023;9(9):1230–1237.
- Konstantinopoulos P, et al. Cancer Discov. 2015;5(11):1137–1154.
Abbreviations
1L, first-line; FIGO, Federation of Gynaecology and Obstetrics; MoA, mechanism of action.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 4411 or UKSafety@gsk.com
February 2026 | PM-GB-NRP-WCNT-240005
